Serum Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukast

Launched by SOUTH VALLEY UNIVERSITY · Mar 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the relationship between a specific molecule in the blood called serum soluble intercellular adhesion molecule-1 (sICAM-1) and acne vulgaris, a common skin condition. The researchers want to see how the levels of this molecule change in people with moderate to severe acne compared to those without acne. They are also interested in understanding how this molecule might be linked to the severity of acne and how treatment with a medication called Montelukast affects its levels.

To participate in this study, you need to be between 15 and 35 years old, have moderate to severe acne, and not be on any acne treatments for at least two weeks or two months, depending on the type of treatment. Unfortunately, some individuals won't be eligible, including pregnant or breastfeeding women, those with certain health conditions like diabetes or high blood pressure, and individuals with specific types of severe acne or other chronic diseases. If you participate, you can expect to provide some blood samples for testing and help researchers learn more about acne and its treatments. This study is still in the planning stages and hasn't started recruiting participants yet.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy persons of both sexes with moderate and severe acne vulgaris.
• • Patients age between 15-35 years
• • Patients with acne vulgaris not receiving any topical or systemic treatments for acne at least 2 weeks and 2 month before the study ,respectively
• Exclusion Criteria:
• • Pregnant and lactating women
• • Diabetics
• • Hypertensive patients
• • acne conglobate patients and acne fulminans patients
• • patients with history of polycystic ovaries syndrome
• • Patients with history of thyroid dysfunction
• • Patients with history of chronic inflammatory or immune-mediated diseases as Crohn's disease, vascular dementia, systemic sclerosis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis and SAPHO syndrome.
• • Any history of hypersensitivity reaction to the studied drug